Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyntra BioLTS:0IL8 +3.54%50 Receivables Turnover is 1.42 as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.52 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 841 Biotechnology companies, Kyntra Bio ranks better than 62.07% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kyntra Bio's Revenue for the
three
months ended in Mar. 2026 was $3.74 Mil. Kyntra Bio's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.63 Mil.
Hence, Kyntra Bio's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.42.
Kyntra Bio (LTS:0IL8) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kyntra Bio Receivables Turnover Related Terms
Kyntra Bio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs TVGN, PSTV, GRDX: Receivables Turnover Comparison
For the Biotechnology subindustry, Kyntra Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Receivables Turnover of 1.42 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #319 out of 841 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Kyntra Bio's Receivables Turnover too high?
Kyntra Bio's current Receivables Turnover is 1.42. The Biotechnology industry median Receivables Turnover is 5.29. Kyntra Bio's value of 1.42 is 73.2% below this industry median. Based on the distribution chart, Kyntra Bio ranks #319 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Receivables Turnover compare to TVGN and PSTV?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #319 out of 841 companies for Receivables Turnover. This puts Kyntra Bio in the upper half of its industry. The industry median Receivables Turnover is 5.29. Kyntra Bio's value of 1.42 is 73.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyntra Bio's current Receivables Turnover of 1.42 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current Receivables Turnover is 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.52, compared to a current price of $7.25 — trading 31.3% above its estimated fair value. The current Receivables Turnover is 1.42 and 73.2% below the Biotechnology industry median of 5.29. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Receivables Turnover is 1.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.25 is trading 31.3% above its estimated GF Value™ of $5.52.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
Receivables Turnover: 1.42
GF Value™: $5.52 vs. price of $7.25 (31.3% above fair value)
Industry Position: 73.2% below the Biotechnology median (#319 of 841)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
